10-Q: Polomar Health Services Reports Deepening Losses, Going Concern Warning

Polomar Health Services reported a significant increase in net losses and a substantial decline in revenue, raising concerns about its ability to continue operations.

Summary

• Polomar Health Services (PMHS) reported a net loss of $1,712,193 for the nine months ended September 30, 2025, a significant increase from the $622,544 net loss for the same period in 2024.
• Revenue for the nine months ended September 30, 2025, decreased to $16,174, down from $37,954 in the prior year, primarily due to a business model transition from local dermatological compounding to national online fulfillment of GLP-1 agonist and erectile dysfunction drugs.
• Operating expenses surged by 256% to $1,618,886 for the nine months ended September 30, 2025, driven by increased legal, accounting, consulting fees, depreciation, amortization, stock-based compensation, and payroll.
• The company had only $38,854 cash on hand and a working capital deficit of ($1,305,466) as of September 30, 2025, leading management to express substantial doubt about its ability to continue as a going concern.
• PMHS secured a one-year non-exclusive pharmacy services agreement with CareValidate, Inc. to fulfill GLP-1 agonist prescriptions, with fulfillment commencing on October 6, 2025, and expected steady revenue growth.
• An Amended and Restated Product Fulfillment and Distribution Agreement with ForHumanity Health, Inc. grants exclusivity for inhalable sildenafil and eletriptan, including a $750,000 product purchase guarantee, of which $200,000 was received by September 30, 2025, with remaining payments extended.
• PMHS plans to launch new online platforms, SlimRx (weight loss) in early 2026 and PoloMeds (diabetes, men's health) in Q1 2026.
• The company is pursuing a merger with Altanine Inc., where former Altanine stockholders are expected to own approximately 80% of the combined entity.
• Material weaknesses in internal control over financial reporting were identified, including inadequate segregation of duties and insufficient written policies.
• PMHS continues to rely heavily on related-party promissory notes for financing, with significant outstanding balances and high interest rates.

Sentiment

Score: 2

Explanation: The company faces severe financial challenges, including significant and increasing losses, declining revenue, a going concern warning, and material weaknesses in internal controls. While there are new contracts and planned product launches, the current financial state and heavy reliance on high-interest related-party debt indicate extremely high risk and a precarious operational outlook.

Positives

• Secured a one-year non-exclusive pharmacy services agreement with CareValidate, Inc. for GLP-1 agonist prescriptions, with fulfillment starting October 6, 2025, and expected steady revenue growth.
• Entered into an Amended and Restated Product Fulfillment and Distribution Agreement with ForHumanity Health, Inc. for exclusive marketing of inhalable sildenafil and eletriptan, including a product purchase guarantee of $750,000.
• Resolved unexpected supply chain issues for imported active pharmaceutical ingredients, which had caused manufacturing delays.
• Plans to launch new online platforms, SlimRx (weight loss) in early 2026 and PoloMeds (diabetes, men's health) in Q1 2026, which could diversify revenue streams.
• Actively seeking licenses and authorization to provide prescription medications in additional U.S. states by the end of 2025 and early 2026.
• The proposed Altanine Merger, if completed, is expected to result in former Altanine stockholders owning approximately 80% of the combined entity, potentially bringing new capital or strategic direction.

Negatives

• Net loss significantly increased to $1,712,193 for the nine months ended September 30, 2025, from $622,544 in the prior year.
• Revenue declined substantially to $16,174 for the nine months ended September 30, 2025, from $37,954 in the prior year, representing a decrease of over 57%.
• Operating expenses increased by 256% to $1,618,886 for the nine months ended September 30, 2025.
• The company has insufficient cash ($38,854) and a negative working capital of ($1,305,466) as of September 30, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern within one year.
• Experienced continuing delays in fully developing compounded product formulations and logistical challenges in transitioning to a national fulfillment model.
• Insufficient access to capital to successfully implement its business plan.
• Delays in receiving exclusivity payments from ForHumanity Health, Inc., with a $50,000 payment extended to November 21, 2025, and the remaining $500,000 expected by December 31, 2025.
• Identified material weaknesses in internal control over financial reporting, including inadequate segregation of duties and insufficient written policies.
• Heavy reliance on related-party loans with high interest rates, ranging from 12% to 18% APR.

Risks

• Uncertainty of profitability due to a history of losses and negative cash flows from operations.
• Failure to obtain adequate financing on a timely basis and on acceptable terms to continue as a going concern.
• Operational uncertainties and delays related to fully developing compounded product formulations, manufacturing, and scaling to a national fulfillment business model.
• Uncertainty with respect to intellectual property rights, protecting those rights, and potential claims of infringement of others' intellectual property.
• Legislative or regulatory changes concerning compounding pharmacies and specific drug categories (e.g., GLP-1 agonists, inhalable formulations not FDA approved).
• Intense competition in the pharmaceutical and telehealth markets.
• Cybersecurity concerns related to operating online platforms and handling sensitive patient data.
• High dependence on third-party utilization of compounded drug formulations.
• Risks associated with related party transactions, including high interest costs and potential conflicts of interest.
• The Altanine Merger is subject to terms and conditions, and its consummation is not guaranteed, potentially impacting strategic direction and capital access.

Future Outlook

The company expects steady revenue growth from its new contract with CareValidate, Inc. for GLP-1 agonist prescriptions, which began fulfillment on October 6, 2025. It plans to launch its SlimRx weight loss platform in early 2026 and PoloMeds for diabetes and men's health in the first quarter of 2026. The company is actively seeking additional state licenses to expand its prescription fulfillment capacity. Management plans to raise additional capital upon the closing of the Altanine Merger transaction and invest working capital in pharmacy operations and other business opportunities, though there is no guarantee of securing sufficient capital.

Management Comments

• We expect steady revenue growth from this customer [CareValidate].
• Management is currently in the process of looking for additional investors.
• Management evaluated all relevant conditions and events... and determined that substantial doubt exists about the Company's ability to continue as a going concern.
• The Company has had insufficient access to capital to successfully implement its business plan.
• Polomar Pharmacy has experienced significant losses from operations as a result of a decline in revenues and increased labor costs.
• Polomar Pharmacy has experienced continuing delays in fully developing its compounded product formulations, manufacturing delays due to unexpected supply chain issues for imported active pharmaceutical ingredients and related products excipients, which have been satisfactorily resolved, and logistical challenges resulting from transitioning from a local fulfillment to national fulfillment business model.

Industry Context

The company operates in the compounding pharmacy sector, which is experiencing growth, particularly in areas like GLP-1 agonists for weight loss and men's health medications. The shift towards telehealth platforms for prescription fulfillment is a significant industry trend that Polomar is attempting to leverage with its CareValidate and ForHumanity agreements, and planned SlimRx and PoloMeds platforms. However, the market for compounded drugs, especially those not FDA-approved in their specific formulation (like inhalable sildenafil/eletriptan), carries regulatory scrutiny and competition from established pharmaceutical companies. The reliance on third-party telehealth networks for patient acquisition is a common model but also introduces dependency risks.

Comparison to Industry Standards

• The company's financial performance, characterized by significant and increasing net losses and declining revenue, is well below industry standards for a healthy, growing pharmaceutical or healthcare services company.
• The explicit 'going concern' warning indicates a severe financial distress level, which is a critical deviation from standard financial health in the industry.
• The high interest rates on related-party loans (12-18% APR) suggest a lack of access to conventional, lower-cost financing, which is not typical for financially stable industry players.
• The identified material weaknesses in internal controls (inadequate segregation of duties, insufficient written policies) are governance concerns that fall below industry best practices.

Management Changes

Corporate Governance

Related Party Transactions

• Promissory Note and Loan Agreement with Reprise Management, Inc. (an affiliate of Daniel Gordon, who controls CWR), with an outstanding principal of $686,403.74 plus $18,815 accrued interest as of September 30, 2025, due July 31, 2027, at 12% annual interest.
• Promissory Note and Loan Agreement with CWR 1, LLC (an affiliate of Daniel Gordon), with draws of $172,136.16 plus $2,152 accrued interest as of September 30, 2025, due October 31, 2025, at 12% APR (increasing to prime + 7% if not paid, and 18% for additional principal after the initial period). An amendment increased the principal amount by $150,000 to $300,000 for manufacturing costs of inhalable sildenafil, subject to a 3% discount per draw.
• Promissory Note and Loan Agreement with Profesco Holdings, LLC (managed by Terrence M. Tierney, CEO), with draws of $114,878.36 as of September 30, 2025, due October 31, 2025, at 12% APR (increasing to prime + 7% if not paid, and 18% for additional principal after January 1, 2026). An amendment increased the principal amount by $100,000 to $200,000, subject to a 3% origination fee and 15% simple interest on additional principal.
• Daniel Gordon, CWR's manager, controls or beneficially owns approximately 42% of the company's issued and outstanding common stock.
• Terrence M. Tierney, the company's CEO, President, and Secretary, is the sole member and manager of Profesco Holdings.
• License Agreement with Pinata Holdings, Inc. (an affiliate of CWR) for patent-pending intellectual property rights, with royalties ranging from 10% to 20% of net sales.

Stakeholder Impact

• Shareholders face significant dilution risk from the Altanine merger (former Altanine stockholders expected to own 80%) and potential for further dilution from future capital raises, alongside substantial losses impacting share value.
• Employees, including management, are subject to changes in roles and compensation structures, but also face uncertainty due to the company's going concern status.
• Customers (e.g., CareValidate, ForHumanity) may benefit from new products and fulfillment services, but also bear risks related to the company's financial stability and potential operational delays.
• Creditors, particularly related parties, are exposed to the company's financial distress and going concern risk, despite receiving high interest rates on their loans.

Next Steps

• Launch SlimRx weight loss online platform in early 2026.
• Launch PoloMeds online platform for diabetes and men's health in Q1 2026.
• Continue seeking licenses and authorization to provide prescription medications in additional U.S. states by the end of 2025 and early 2026.
• Close the Altanine Merger transaction.
• Raise additional capital to fund operations.
• Address material weaknesses in internal control over financial reporting.
• Receive remaining exclusivity payments from ForHumanity Health, Inc. ($50,000 by November 21, 2025, and $500,000 by December 31, 2025).
• Utilize reasonable commercial efforts to have clinical PK data on inhalable eletriptan within 90 days of August 14, 2025.

Key Dates

Recommendation

The company is in a precarious financial position, evidenced by substantial and increasing net losses, declining revenue, a significant working capital deficit, and an explicit 'going concern' warning from management. While new contracts and planned product launches offer potential, the current financial instability, heavy reliance on high-interest related-party debt, and material weaknesses in internal controls present severe risks. The proposed Altanine merger, while potentially bringing capital, also implies significant dilution for existing shareholders. These factors collectively point to a high probability of further value erosion, making it a strong sell recommendation for investors.

Keywords

Compounding Pharmacy, GLP-1 Agonists, Telehealth, Weight Loss Medications, Erectile Dysfunction Drugs, Inhalable Sildenafil, Inhalable Eletriptan, Pharmaceutical Distribution, SEC Filing, Going Concern, Financial Losses, Capital Raise, Altanine Merger, SlimRx, PoloMeds